**Table S1:** Factors associated with overall survival (OS1) among enrolled patients (those who were lost to follow-up are considered as death, choose those variables with *p*<0.1 into multivariate analysis) (n=127)

|  |  |
| --- | --- |
| Factors | OS1 |
| Univariate | Multivariate |
| HR | *p*-value | HR (95%CI) |
| Age group (≥ 50 years vs.<50 years ) | 1.061 | 0.814 |  |
| ER (Positive vs. Negative) | 0.764 | 0.279 |  |
| PR (Positive vs. Negative) | 0.752 | 0.268 |  |
| HER2 (Negative vs. Positive) | 1.121 | 0.658 |  |
| TNBC (Yes vs. No) | 1.704 | **0.062** | 1.807(1.031- 3.168) |
| Number of metastatic sites (≥2 sites vs. <2) | 1.607 | 0.108 |  |
| Type of metastatic sites |  |  |  |
|  2\* vs. 1\* | 1.401 | 0.238 |  |
|  3\* vs. 1\* | 1.327 | 0.457 |  |
| Eribulin line of therapy (Late-line vs. Early-line) | 2.134 | **0.028** | 2.228(1.133- 4.382) |
| HR=hazard ratio; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2, TNBC=triple negative breast cancer, 1\*=Non-visceral metastasis and/or recurrent disease, 2\*=Both visceral and non-visceral metastasis, 3\*=Visceral metastasis |